Table 1: Patient characteristics - by exposure group.
ASA/Clopidogrel | ASA only | Clopidogrel only | Not exposed | ||
---|---|---|---|---|---|
Characteristic | (n = 23) | (n = 99) | (n = 13) | (n = 271) | P value |
Age, mean ± sd | 67.4 ± 11.6 | 66.8 ± 13.4 | 68.5 ± 8.7 | 58.7 ± 14.3 | < 0.001 |
Gender, % (n) | 0.86 | ||||
Male | 43.5 (10) | 53.1 (51) | 53.8 (7) | 52.6 (141) | |
Female | 56.5 (13) | 46.9 (45) | 46.2 (6) | 47.4 (127) | |
Race/ethnicity | 0.84 | ||||
Black | 13.0 (3) | 12.2 (12) | 15.4 (2) | 7.5 (20) | |
Asian | 0 (0) | 0 (0) | 0 (0) | 1.1 (3) | |
White | 87.0 (20) | 82.7 (81) | 84.6 (11) | 86.8 (231) | |
Hispanic | 0 (0) | 0 (0) | 0 (0) | 0.8 (2) | |
Other | 0 (0) | 5.0 (5) | 0 (0) | 3.8 (10) | |
Insurance payor | 0.004 | ||||
Commercial | 0 (0) | 1.0 (1) | 0 (0) | 3.0 (8) | |
Managed | 4.3 (1) | 22.4 (22) | 7.7 (1) | 30.8 (82) | |
Medicaid | 17.4 (4) | 8.2 (8) | 0 (0) | 8.3 (22) | |
Medicaid managed | 8.7 (2) | 2.0 (2) | 15.4 (2) | 7.5 (20) | |
Medicare | 47.8 (11) | 45.9 (45) | 38.5 (5) | 33.1 (88) | |
Medicare managed | 17.4 (4) | 16.3 (16) | 38.5 (5) | 7.5 (20) | |
Self-pay | 4.3 (1) | 4.1 (4) | 0 (0) | 9.4 (25) | |
Workers comp | 0 (0) | 0 (0) | 0 (0) | 0.4 (1) | |
BMI, mean ± sd | 28.1 ± 7.7 | 27.4 ± 6.5 | 30.9 ± 8.0 | 27.9 ± 7.8 | 0.49 |
Comorbidities, % (n) | |||||
COPD | 47.8 (11) | 25.3 (25) | 53.8 (7) | 26.3 (71) | 0.02 |
DM | 30.4 (7) | 34.3 (34) | 38.5 (5) | 17.8 (48) | 0.003 |
CHF | 8.7 (2) | 10.1 (10) | 7.7 (1) | 5.2 (14) | 0.39 |
CAD/MI | 52.2 (12) | 26.3 (28) | 61.5 (8) | 9.6 (26) | < 0.001 |
ESRD (Stage V) | 0 (0) | 3.0 (3) | 0 (0) | 1.1 (3) | 0.49 |
CVA/TIA | 17.4 (4) | 15.2 (15) | 46.2 (6) | 4.4 (12) | < 0.001 |
HTN | 65.2 (15) | 62.6 (62) | 76.9 (10) | 45.6 (123) | 0.003 |
Cancer | 13.0 (3) | 15.2 (15) | 23.1 (3) | 16.3 (44) | 0.87 |
Cirrhosis | 0 (0) | 0 (0) | 0 (0) | 1.5 (4) | 0.57 |
On DVT prophylaxis | 52.2 (12) | 62.6 (62) | 30.8 (4) | 47.2 (126) | 0.03 |